UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2025
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
This
Report of Foreign Private Issuer on Form 6-K consists of (i) NLS Pharmaceutics Ltd.’s, or the Registrant’s, Unaudited Interim
Condensed Financial Statements as of June 30, 2025 and December 31, 2024 and for the six months ended June 30, 2025 and 2024, which are
attached hereto as Exhibit 99.1; and (ii) the Registrant’s Management’s Discussion and Analysis of Financial Condition and
Results of Operations for the six months ended June 30, 2025, which is attached hereto as Exhibit 99.2.
EXHIBIT INDEX
Exhibit
Number |
|
Description of Document |
| 99.1 |
|
Unaudited Interim Condensed Financial Statements of NLS Pharmaceutics Ltd. as of June 30, 2025 and December 31, 2024 and for the six months ended June 30, 2025 and 2024. |
| 99.2 |
|
Management’s Discussion and
Analysis of Financial Condition and Results of Operations of NLS Pharmaceutics Ltd
for the six months ended June 30, 2025. |
| 101.INS |
|
Inline XBRL Instance Document |
| 101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NLS Pharmaceutics Ltd. |
| |
|
| Date: October 3, 2025 |
By: |
/s/ Alexander Zwyer |
| |
|
Name: |
Alexander Zwyer |
| |
|
Title: |
Chief Executive Officer |
